Vertex Pharmaceuticals Incorporated (VRTX) Tax Rate: 14.86%
Is Vertex Pharmaceuticals Incorporated’s tax rate high or low?
Vertex Pharmaceuticals Incorporated's tax rate of 14.86% is 78% below its 5-year average of 66.08%, near the low end of its 5-year range (13.00%–315.53%).
The tax rate for Vertex Pharmaceuticals Incorporated (VRTX) is 14.86%. It is below its 12-month average by 91.00% (165.19%).
VRTX Tax Rate Chart
VRTX Average Tax Rate Chart
VRTX Current vs Average Tax Rate Chart
VRTX Tax Rate Metrics
TAX RATE
14.86%
TAX RATE AVG TTM
165.19%
TAX RATE AVG 3Y
92.31%
TAX RATE AVG 5Y
66.08%
TAX RATE AVG 10Y
74.39%
TAX RATE AVG 15Y
35.36%
TAX RATE AVG 20Y
26.23%
CURRENT VS TTM AVG
-91.00%
CURRENT VS 3Y AVG
-83.90%
CURRENT VS 5Y AVG
-77.51%
CURRENT VS 10Y AVG
-80.02%
CURRENT VS 15Y AVG
-57.98%
CURRENT VS 20Y AVG
-43.34%
Vertex Pharmaceuticals Incorporated Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Tax Rate FAQ
- What is the tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The tax rate for VRTX stock is 14.86%.
- Is Vertex Pharmaceuticals Incorporated's tax rate high or low?
- Vertex Pharmaceuticals Incorporated's tax rate of 14.86% is 78% below its 5-year average of 66.08%, near the low end of its 5-year range (13.00%–315.53%).
- What is the TTM average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average tax rate for VRTX stock is 165.19%.
- What is the 3Y average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average tax rate for VRTX stock is 92.31%.
- What is the 5Y average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average tax rate for VRTX stock is 66.08%.
- What is the 10Y average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average tax rate for VRTX stock is 74.39%.
- What is the 15Y average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average tax rate for VRTX stock is 35.36%.
- What is the 20Y average tax rate for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average tax rate for VRTX stock is 26.23%.
Vertex Pharmaceuticals Incorporated Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 14.86% |
| 2024-12-31 | 315.53% |
| 2023-12-31 | 17.36% |
| 2022-12-31 | 21.51% |
| 2021-12-31 | 14.22% |
| 2020-12-31 | 13.00% |
| 2019-12-31 | 15.64% |
| 2018-12-31 | -247.71% |
| 2017-12-31 | 684.07% |
| 2016-12-31 | -24.74% |
| 2015-12-31 | -5.43% |
| 2014-12-31 | -0.95% |
| 2013-12-31 | 29.56% |
| 2012-12-31 | -313.01% |
| 2011-12-31 | 31.87% |
| 2010-12-31 | 0.00% |
| 2009-12-31 | 0.00% |
| 2008-12-31 | 6.62% |
| 2007-12-31 | 5.01% |
| 2006-12-31 | 8.94% |
| 2005-12-31 | -35.57% |
| 2004-12-31 | -18.30% |
| 2003-12-31 | -6.93% |
| 2002-12-31 | 9.18% |
| 2001-12-31 | 1.63% |
| 2000-12-31 | -1.82% |
| 1999-12-31 | -3.47% |
| 1996-12-31 | -25.82% |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani